Gene · 7280
TUBB2A: tubulin beta 2A class IIa
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBB2A: tubulin beta 2A class IIa. Genes, record 7280. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7280
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13885 | Tubulin beta-2A chain | 445 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents42
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 10301 | Q13885 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10301 | Q13885 | Espacenet |
| US 11860162 B2 | 2024-01-02 | 1410 | Q13885 | Espacenet |
| JP 2023106701 A | 2023-08-02 | 24 | Q13885 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5579 | Q13885 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93577 | Q13885 | Espacenet |
| JP 2022092366 A | 2022-06-22 | 591 | Q13885 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196548 | Q13885 | Espacenet |
| US 11278629 B2 | 2022-03-22 | 36 | Q13885 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 12151 | Q13885 | Espacenet |
1 to 10 of 42
See all 42 patentsDrugs91
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-751 | CHEMBL20684 | Tubulin beta inhibitor | INHIBITOR | ChEMBL |
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 91
See all 91 drugsTrials8,740
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,740
See all 8,740 trialsNIH grants819
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBB2A papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| R01CA157823 | Genetic Susceptibility and Biomarkers of Platinum-related Toxicities | 3 | 2025 |
| R01NS058721 | ACC: Callosal Agenesis as a Window into Common Neurodevelopmental Disorders | 3 | 2025 |
| P30CA014599 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 2 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 2 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 2 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 2 | 2025 |
1 to 10 of 819Source NIH's project files
See all 819 nih grantsPapers1,014
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative toxicoproteomics reveals distinct proteostasis and ribosomal stress signatures of CMIT and PHMG. | Toxicol In Vitro | 2027 | 42702274 | PubTator, text mining | PubMed |
| Developmental Profiles Associated with TUBA1A, TUBB2A, TUBB2B, and TUBB3 Tubulinopathy Conditions. | Am J Intellect Dev Disabil | 2026 | 42593952 | PubTator, text mining | PubMed |
| Genotypic and phenotypic heterogeneity in tubulinopathies: insights from a Turkish multicenter cohort. | Neurol Sci | 2026 | 42472988 | PubTator, text mining | PubMed |
| Immunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunity. | Front Tuberc | 2026 | 42368172 | PubTator, text mining | PubMed |
| Genetic and Molecular Interconnections Between Chronic Obstructive Pulmonary Disease and Osteoporosis: Insights from Single-Cell and Mendelian Randomization Analyses. | Int J Chron Obstruct Pulmon Dis | 2026 | 42180802 | PubTator, text mining | PubMed |
| Investigating the Function of C‑Terminal Tails of Human Tubulin Isotypes in the Motility Regulation of Cytoplasmic Dynein. | ACS Omega | 2026 | 42179625 | PubTator, text mining | PubMed |
| Decoding Pathogenic Mutational Landscapes in Alzheimer's Disease Through Integrated Transcriptomics. | Hum Mutat | 2026 | 42131724 | PubTator, text mining | PubMed |
| Integrative single-cell and spatial multi-Omics analyses identify NETs-driven colon cancer subtypes with distinct metabolic features and prognostic implications. | J Transl Med | 2026 | 42106773 | PubTator, text mining | PubMed |
| A Novel TUBB2A Variant Causing Ataxia With Preserved Ambulation Into Adulthood. | Am J Med Genet A | 2026 | 42050746 | PubTator, text mining | PubMed |
| Novel Prognostic and Predictive miRNA Biomarkers Shape the Landscape of T Cell Dysfunction in Cancer. | J Cell Mol Med | 2026 | 41923561 | PubTator, text mining | PubMed |
1 to 10 of 1,014
See all 1,014 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7280
GET https://conductscience.org/api/genes/v1/7280/patents?page=2